Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Blanche Elizabeth Saldanha has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199223-09-2014
23-09-2014
SEBI (Prohibition of Insider Trading) Regulations, 1992
Blanche Elizabeth Saldanha has submitted the SEBI (Prohibition of Insider Trading) Regulations, 199222-09-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199218-09-2014
Glenmarks TRPA1 antagonist GRC 17536 shows positive data in a proof of concept study
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 17, 2014 titled "Glenmarks TRPA1 antagonist GRC 17536 shows positive data in a proof of concept study".17-09-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199211-09-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199201-09-2014
Updates on Outcome of AGM
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the proceedings of the 36th Annual General Meeting (AGM) of the Company held on July 25, 2014.25-08-2014
Outcome of Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on August 22, 2014 allotted 14,750 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.22-08-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199222-08-2014
Glenmark enters Oncology with the Discovery and the Initiation of IND enabling Studies of an innovative bispecific Antibody
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated August 20, 2014, titled "Glenmark enters Oncology with the Discovery and the Initiation of IND enabling Studies of an innovative bispecific Antibody"20-08-2014